Historique
Bulletin de Périodique
Addiction , Vol.115, n°7 - July 2020
Paru le :
01/07/2020
Article en page(s) :
1201-1408
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- Extra-medical use of antipsychotics: what can be learnt from experiences with other prescription medicines? [Editorial]. Gisev N., Brett J., Peacock A., p. 1203-1205.
- 'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration [Addiction Opinion and Debate]. Freeman T.P., Lorenzetti V., p. 1207-1216.
- How experimental cannabinoid studies will inform the standardized THC unit. Chester L., Chesney E., Oliver D., Wilson J., Englund A., p. 1217-1218.
- The viability of a standard THC unit. Filbey F.M., p. 1218-1219.
- Importance of a standard unit dose for cannabis research. Volkow N.D., Weiss S.R.B., p. 1219-1221.
- Standard tetrahydrocannabinol units: an idea whose time has come. Hammond D., p. 1221-1222.
- Moving forwards with the standard THC unit. Freeman T.P., Lorenzetti V., p. 1222-1223.
- Effect of alcohol use disorders and alcohol intake on the risk of subsequent depressive symptoms: a systematic review and meta-analysis of cohort studies. Li J., Wang H., Li M., Shen Q., Li X., Zhang Y., et al., p. 1224-1243.
- The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Mahmud S., Mumtaz G.R., Chemaitelly H., Al Kanaani Z., Kouyoumjian S.P., Hermez J.G., et al., p. 1244-1262.
- Commentary on Mahmud et al. (2020): Hepatitis C elimination efforts need to include people who inject drugs in the Middle East and North Africa. Walsh N., p. 1263-1264.
- Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Rigal L., Sidorkiewicz S., Tréluyer J.M., Perrodeau E., Le Jeunne C., Porcher R., et al., p. 1265-1276.
- Toxic trade: the impact of preferential trade agreements on alcohol imports from Australia in partner countries. Schram A., Aisbett E., Townsend B., Labonté R., Baum F., Friel S., p. 1277-1284.
- Relationships between US state alcohol policies and alcohol outcomes: differences by gender and race/ethnicity. Subbaraman M.S., Mulia N., Kerr W.C., Patterson D., Karriker-Jaffe K.J., Greenfield T.K., p. 1285-1294.
- Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Larance B., Degenhardt L., Grebely J., Nielsen S., Bruno R., Dietze P., et al., p. 1295-1305.
- Commentary on Larance et al. (2020): Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine. Shover C.L., p. 1306-1307.
- Using contributing causes of death improves prediction of opioid involvement in unclassified drug overdoses in US death records. Boslett A.J., Denham A., Hill E.L., p. 1308-1317.
- Commentary on Boslett et al. (2020): Towards better measurement of drug involvement in fatal overdoses. Ruhm C.J., p. 1318-1319.
- Self-reported exposure to, perceptions about, and attitudes about public marijuana smoking among US adults, 2018. Schauer G.L., Tynan M.A., Marynak K., p. 1320-1329.
- Behavioral couples therapy versus cognitive behavioral therapy for problem gambling: a randomized controlled trial. Nilsson A., Magnusson K., Carlbring P., Andersson G., Hellner C., p. 1330-1342.
- Commentary on Nilsson et al. (2020): The development of effective interventions for concerned significant others affected by gambling harms. Dowling N.A., p. 1343-1344.
- Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a cluster-randomized controlled trial. Guillaumier A., Skelton E., Shakeshaft A., Farrell M., Tzelepis F., Walsberger S., et al., p. 1345-1355.
- Commentary on Guillaumier et al. (2020): Is harm reduction a suitable outcome for historically hard-to-treat smokers? McClure E.A., Carpenter M.J., p. 1356-1357.
- Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial. Carpenter M.J., Wahlquist A.E., Dahne J., Gray K.M., Garrett-Mayer E., Cummings K.M., et al., p. 1358-1367.
- Genetic liability to ADHD and substance use disorders in individuals with ADHD. Wimberley T., Agerbo E., Horsdal H.T., Ottosen C., Brikell I., Als T.D., et al., p. 1368-1377.
- On the legacy of normalization. Duff C., p. 1378-1381.
- Development of a computerized adaptive substance use disorder scale for screening and measurement: the CAT-SUD. Gibbons R.D., Alegria M., Markle S., Fuentes L., Zhang L., Carmona R., et al., p. 1382-1394.
- The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity? Ekhtiari H., Noroozi A., Farhoudian A., Radfar S.R., Hajebi A., Sefatian S., et al., p. 1395-1403.
- Extra-medical use of antipsychotics: what can be learnt from experiences with other prescription medicines? [Editorial]. Gisev N., Brett J., Peacock A., p. 1203-1205.
- 'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration [Addiction Opinion and Debate]. Freeman T.P., Lorenzetti V., p. 1207-1216.
- How experimental cannabinoid studies will inform the standardized THC unit. Chester L., Chesney E., Oliver D., Wilson J., Englund A., p. 1217-1218.
- The viability of a standard THC unit. Filbey F.M., p. 1218-1219.
- Importance of a standard unit dose for cannabis research. Volkow N.D., Weiss S.R.B., p. 1219-1221.
- Standard tetrahydrocannabinol units: an idea whose time has come. Hammond D., p. 1221-1222.
- Moving forwards with the standard THC unit. Freeman T.P., Lorenzetti V., p. 1222-1223.
- Effect of alcohol use disorders and alcohol intake on the risk of subsequent depressive symptoms: a systematic review and meta-analysis of cohort studies. Li J., Wang H., Li M., Shen Q., Li X., Zhang Y., et al., p. 1224-1243.
- The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Mahmud S., Mumtaz G.R., Chemaitelly H., Al Kanaani Z., Kouyoumjian S.P., Hermez J.G., et al., p. 1244-1262.
- Commentary on Mahmud et al. (2020): Hepatitis C elimination efforts need to include people who inject drugs in the Middle East and North Africa. Walsh N., p. 1263-1264.
- Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Rigal L., Sidorkiewicz S., Tréluyer J.M., Perrodeau E., Le Jeunne C., Porcher R., et al., p. 1265-1276.
- Toxic trade: the impact of preferential trade agreements on alcohol imports from Australia in partner countries. Schram A., Aisbett E., Townsend B., Labonté R., Baum F., Friel S., p. 1277-1284.
- Relationships between US state alcohol policies and alcohol outcomes: differences by gender and race/ethnicity. Subbaraman M.S., Mulia N., Kerr W.C., Patterson D., Karriker-Jaffe K.J., Greenfield T.K., p. 1285-1294.
- Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Larance B., Degenhardt L., Grebely J., Nielsen S., Bruno R., Dietze P., et al., p. 1295-1305.
- Commentary on Larance et al. (2020): Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine. Shover C.L., p. 1306-1307.
- Using contributing causes of death improves prediction of opioid involvement in unclassified drug overdoses in US death records. Boslett A.J., Denham A., Hill E.L., p. 1308-1317.
- Commentary on Boslett et al. (2020): Towards better measurement of drug involvement in fatal overdoses. Ruhm C.J., p. 1318-1319.
- Self-reported exposure to, perceptions about, and attitudes about public marijuana smoking among US adults, 2018. Schauer G.L., Tynan M.A., Marynak K., p. 1320-1329.
- Behavioral couples therapy versus cognitive behavioral therapy for problem gambling: a randomized controlled trial. Nilsson A., Magnusson K., Carlbring P., Andersson G., Hellner C., p. 1330-1342.
- Commentary on Nilsson et al. (2020): The development of effective interventions for concerned significant others affected by gambling harms. Dowling N.A., p. 1343-1344.
- Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a cluster-randomized controlled trial. Guillaumier A., Skelton E., Shakeshaft A., Farrell M., Tzelepis F., Walsberger S., et al., p. 1345-1355.
- Commentary on Guillaumier et al. (2020): Is harm reduction a suitable outcome for historically hard-to-treat smokers? McClure E.A., Carpenter M.J., p. 1356-1357.
- Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial. Carpenter M.J., Wahlquist A.E., Dahne J., Gray K.M., Garrett-Mayer E., Cummings K.M., et al., p. 1358-1367.
- Genetic liability to ADHD and substance use disorders in individuals with ADHD. Wimberley T., Agerbo E., Horsdal H.T., Ottosen C., Brikell I., Als T.D., et al., p. 1368-1377.
- On the legacy of normalization. Duff C., p. 1378-1381.
- Development of a computerized adaptive substance use disorder scale for screening and measurement: the CAT-SUD. Gibbons R.D., Alegria M., Markle S., Fuentes L., Zhang L., Carmona R., et al., p. 1382-1394.
- The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity? Ekhtiari H., Noroozi A., Farhoudian A., Radfar S.R., Hajebi A., Sefatian S., et al., p. 1395-1403.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Dépouillements
Ajouter le résultat à votre sélection
BACKGROUND AND AIMS: Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while [...]
L. RIGAL ;
S. SIDORKIEWICZ ;
J. M. TRELUYER ;
E. PERRODEAU ;
C. LE JEUNNE ;
R. PORCHER ;
P. JAURY
|
2020
Dans Addiction (Vol.115, n°7, July 2020) Article : Périodique
Dans Addiction (Vol.115, n°7, July 2020) Article : Périodique
Background and Aims: Baclofen is a promising drug for treating patients with alcohol-related disorders. Nevertheless, the first randomized clinical trials (mainly with target doses) reported inconsistent efficacy, possibly because of the effecti[...]